AN OPEN-LABEL, MULTICENTER, PHASE IB/II TRIALEVALUATING THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND EFFICACY OFMOSUNETUZUMAB (BTCT4465A) IN COMBINATIONWITH POLATUZUMAB VEDOTIN IN PATIENTS WITH BCELLNON-HODGKIN LYMPHOMA
MD Anderson Study Status
Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab
This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular lymphoma (FL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy for the treatment of R/R mantle cell lymphoma (MCL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
B-cell Non-Hodgkin Lymphoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.